• Xvivo Perfusion won FDA clearance to enroll more patients in its US PRESERVE CAP study of 60 heart transplants using Heart Assist Transport.
• CMS renewed cost-recovery authorization, supporting continued clinical use while one-year PRESERVE follow-up data are finalized for a PMA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.